

MDPI

Article

# Antiadherent AgBDC Metal-Organic Framework Coating for Escherichia coli Biofilm Inhibition

Ana Arenas-Vivo <sup>1,†,‡</sup>, Vanessa Celis Arias <sup>2,‡</sup>, Georgiana Amariei <sup>3</sup>, Roberto Rosal <sup>3</sup>, Isabel Izquierdo-Barba <sup>4,5</sup>, Tania Hidalgo <sup>1</sup>, María Vallet-Regí <sup>4,5</sup>, Hiram I. Beltrán <sup>2</sup>, Sandra Loera-Serna <sup>2</sup> and Patricia Horcajada <sup>2,\*</sup>

- Advanced Porous Materials Unit (APMU), IMDEA Energy Institute, Avda. Ramón de la Sagra 3, 28935 Móstoles, Spain
- Basic Science Department, Metropolitan-Azcapotzalco Autonomous University (UAM), Av. San Pablo No 180, Col. Revnosa-Tamaulipas, Ciudad de México 02200, Mexico
- <sup>3</sup> Department of Chemical Engineering, University of Alcalá, 28871 Alcalá de Henares, Spain
- <sup>4</sup> Pharmaceutical Chemistry Department, Faculty of Pharmacy, University Complutense of Madrid, Hospital 12 de Octubre i+12 Institute for Health Research, 28040 Madrid, Spain
- <sup>5</sup> CIBER of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
- \* Correspondence: patricia.horcajada@imdea.org
- † Present Addresses: R&D Concrete Lab, Sika, S.A.U, Crta. de Fuencarral, 72, 28108 Alcobendas, Spain.
- ‡ These authors contributed equally to this work.

**Abstract:** Surface microbial colonization and its potential biofilm formation are currently a major unsolved problem, causing almost 75% of human infectious diseases. Pathogenic biofilms are capable of surviving high antibiotic doses, resulting in inefficient treatments and, subsequently, raised infection prevalence rates. Antibacterial coatings have become a promising strategy against the biofilm formation in biomedical devices due to their biocidal activity without compromising the bulk material. Here, we propose for the first time a silver-based metal–organic framework (MOF; here denoted *AgBDC*) showing original antifouling properties able to suppress not only the initial bacterial adhesion, but also the potential surface contamination. Firstly, the AgBDC stability (colloidal, structural and chemical) was confirmed under bacteria culture conditions by using agar diffusion and colony counting assays, evidencing its biocide effect against the challenging *E. coli*, one of the main representative indicators of Gram-negative resistance bacteria. Then, this material was shaped as homogeneous spin-coated AgBDC thin film, investigating its antifouling and biocide features using a combination of complementary procedures such as colony counting, optical density or confocal scanning microscopy, which allowed to visualize for the first time the biofilm impact generated by MOFs via a specific fluorochrome, calcofluor.

Keywords: Metal-organic frameworks; silver; antifouling; bactericide; biofilm; Escherichia coli



Citation: Arenas-Vivo, A.; Celis Arias, V.; Amariei, G.; Rosal, R.; Izquierdo-Barba, I.; Hidalgo, T.; Vallet-Regí, M.; Beltrán, H.I.; Loera-Serna, S.; Horcajada, P. Antiadherent AgBDC Metal-Organic Framework Coating for Escherichia coli Biofilm Inhibition. Pharmaceutics 2023, 15, 301. https://doi.org/ 10.3390/pharmaceutics15010301

Academic Editors: Ionela Andreea Neacsu and Bogdan Stefan Vasile

Received: 25 November 2022 Revised: 30 December 2022 Accepted: 10 January 2023 Published: 16 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

# 1. Introduction

Today more than ever, the threat of bacterial infections is still an unresolved global issue, perpetrating more than 75% of human infectious diseases (e.g., tuberculosis, tetanus, cholera, etc.) [1]. They are mainly associated with the microbial dissemination on different surfaces, leading to large contamination due to the potential biofilm formation in that action place, which is still a current pressing concern [2]. Biofilms are complex microenvironments composed of colonies of microorganisms protected by extracellular polymeric substances (EPS), in which the bacteria are able to communicate and interact between them, generating strategies to defend themselves against any type of external stresses [3]. This harsh microbial environment is one of the reasons behind the complexity of inhibiting biofilms as well as the rising tendency to generate antimicrobial resistances against traditional chemical antibiotics [4]. Thus, shedding light on the biofilm emergence could enhance efficient treatments.

Pharmaceutics **2023**, *15*, 301

Biofilm formation entails four different stages: (i) initial adhesion by planktonic bacteria (in suspension) approaching the substrate; (ii) colony-forming units (CFUs) with a proliferation step; (iii) a subsequently maturation of the biofilm, associated with an EPS generation; and finally, (iv) the biofilm redispersion, completing the entire cycle. Many of the proposed therapeutic strategies have targeted each of these formation stages for their complete eradication [5]; however, just the ones tackling the first cycle phases seem to be more effective (e.g., limiting bacterial adhesion, still in a reversible stage, or preventing the EPS generation) since treating already-contaminated surfaces could lead to an incomplete bacterial death, releasing a larger amount of planktonic bacteria to this microenvironment [2].

Among other recent alternatives, the use of antibacterial coatings has become an upward trend in the scientific community since thin films can provide the desired biocidal effect to the surface without compromising the bulk material features. The design of these linings is based on three main approaches, such as the active ingredients (AIs) release, contact-killing or antiadhesion/bacteria repelling [6]. Despite the reported progress on the topic, there are still some drawbacks to be overcome (e.g., limited reservoirs, lack of long-term effects, potential cytotoxicity, associated inflammatory responses), which has led to novel efficient approaches. Herein, we propose the use of metal-organic frameworks (MOFs) as surface antimicrobial coatings with potential antiadherent properties. MOFs are a promising family of porous crystalline hybrid solids, comprising inorganic nodes (e.g., atoms, clusters, chains) and organic polycomplexant linkers (e.g., carboxylates, phosphonates, azolates) that assemble into multidimensional periodic lattices [7]. Additionally, MOFs have been studied as antibacterial platforms due to their inherent properties (e.g., structural and compositional tunability, ordered distribution of active sites, exceptional porosity) [8–10]. Compared with other classic porous materials, these outstanding features result from: (i) their chemical/structural versatility, which permits a suitable biocompatibility upon chemical design; (ii) an ideal hydrophobic/hydrophilic internal microenvironment conveniently adapted to host a very broad variety of active ingredients (e.g., biological gases, cosmetics, enzymes, nucleic acids, drugs); (iii) releasing them in a controlled manner under physiological conditions; (iv) easy and scalable synthesis, following green methods with high yields; (iv) in vivo safety; and (v) their external surface engineering, endowing further multifunctional abilities, such as furtivity, targeting and imaging, or enhancing their stability (chemical/structural/colloidal) under biorelevant media [11]. In addition, taking into account the well-known biocide character of silver (used in commercial solutions) [11–13], it is no wonder that many publications proposed the use of Ag-based MOFs for antibacterial therapy (see a brief summary in Supplementary Materials, Table S2 [14–35]). Focusing just on the state of the art of those works using Ag-MOF coatings against bacterial biofilm (e.g., AgBTC [14,15], AgBDC-NH<sub>2</sub> [16,17], Ag-imidazolate [18,33], Ag<sub>2</sub>[HBTC][im] [19]), a great inhibition of the colony-growth viability (>80%) was achieved. However, the direct observation of these reported surfaces by means of confocal microscopy showing an active biofilm disruption has not been performed. Therefore, besides their demonstrated biocide properties, no active antifouling Ag-based MOF layers have been yet accomplished.

To the best of our knowledge, there are very few reports targeting the study of MOF coatings for the inhibition of the initial bacterial adhesion, further preventing the biofilm development. Just Zang [36] and Gu [37] considered in their investigations the quantification of the potential adhesion reduction in presence of the MOF coating by determining the CFU via plate counting of the sessile bacteria in the biofilm (anchored to a substrate). In spite of this, their work lacks experimental surface visualization or even the verification of the adhesion process, hindering the support of the bacteria viability. Other work by Lui et al. [38] also attempted to lessen the bacteria attachment by using a composite of iron terephthalate MIL-88B with Ce. This composite was applied for biofilm dispersion and treatment of previously contaminated surfaces, not as biofilm prevention implementation. Finally, another strategy found in the literature, followed by one of the authors of the

Pharmaceutics **2023**, *15*, 301 3 of 17

present work, involved the irradiation of an MOF coating to activate the dispersion of the attached bacteria [39,40]. Although the photoactive-MOF layer reduced the initial number of colonies adhered to the substrate, complete antifouling effect was not achieved until irradiation.

In this case, for the first time, the authors aimed to develop here an active MOF thin film with full antifouling properties that will suppress initial bacterial adhesion, hampering the biofilm formation and, consequently, the surface contamination. The selected MOF structure, denoted AgBDC, was previously reported by Sun et al. [41], being optimized here with a new-fashioned protocol with a simpler and faster reaction for the upscale attainment of AgBDC submicrometric particles (~250 nm). The colloidal, structural and chemical stability of AgBDC was verified under bacteria culture conditions. In a bacteria biofilm model, Escherichia coli (E. coli) biofilms were chosen since they are the major cause of morbidity and mortality behind intestinal infections, are the reason behind the spread of nosocomial infections derived by the contamination of diverse healthcare equipment (e.g., medical devices, joints, shuts, prosthetic grafts) and are one of the most infectious bacteria along with Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa [42,43]. In addition, E. coli is a Gram (–) facultative anaerobic bacterium, which makes it one of the most adaptable organism that could be grown in laboratory conditions, making it an ideal candidate to test the biofilm treatment [44]. Practically, the biocide activity of AgBDC against planktonic E. coli was identified through the agar diffusion assays along with its minimum inhibitory concentration (MIC, ~100 ppm) determined by colony counting. Then, homogeneous spin-coated AgBDC thin films were prepared to investigate their antifouling and biocide properties by a combination of different complementary techniques (confocal microscopy, scanning electron microscopy (SEM), colony counting, optical density  $(OD_{600})$ ). Finally, it should be noted that this this study used, for the first time, a specific fluorochrome (calcofluor) for the direct visualization of the EPS presence via confocal laser scanning microscopy, unveiling and further confirming the absence of biofilm formation.

#### 2. Materials and Methods

#### 2.1. Materials

All the chemicals were used as received. Benzene 1,4-dicarboxylic acid (BDC, MW:  $166.13~{\rm g\cdot mol^{-1}}$ , 98% grade), sodium hydroxide (NaOH, MW:  $40~{\rm g\cdot mol^{-1}}$ , 98% grade) and silver nitrate (AgNO<sub>3</sub>, MW:  $169.87~{\rm g\cdot mol^{-1}}$ , 99% grade) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Anhydrous ethanol (EtOH, 99% of purity, Aldrich) and deionized (DI) water were used as solvents. For the preparation of the bacteriological broth culture known as nutrient broth (NB), beef extract and peptone (pH 7–7.2) were purchased from Condalab (Torrejón de Ardoz, Madrid, Spain).

## 2.2. AgBDC MOF Synthesis and Characterization

# 2.2.1. Synthesis of MOF

AgBDC synthesis ([AgC<sub>4</sub>H<sub>2</sub>O<sub>2</sub>], MW: 190 g·mol<sup>-1</sup>) was optimized from a previous protocol [41]. Briefly, BDC (0.5 g, 3 mmol) and NaOH (0.3 g, 7.5 mmol) were dissolved in 80 mL of deionized (DI) water in a round bottom flask. Then, a 20 mL EtOH solution of AgNO<sub>3</sub> (0.51 g, 3 mmol) was added dropwise over the previous solution, stirring at room temperature (RT) during 24 h. The product was recovered by centrifugation (4032×g RCF, relative centrifugal force, 10 min) and dried out at 50 °C during 12 h. Yield: 43%, dry basis corrected through thermogravimetric analysis (TGA).

For the formation of AgBDC thin-film coatings, a 10 mL water suspension with 25 mg of AgBDC was prepared. With the assistance of a spin coater (SPIN150i, POLOS, program used: 510 rpm, period: 200 ms, amplitude:  $90^{\circ}$ , rotation time: 0.0/30.0 ss.s),  $100 \,\mu\text{L}$  of the abovementioned suspension were deposited over one side of 13 mm diameter cover glass discs (VWR, Darmstadt, Germany) and were dried at RT for analyzing

Pharmaceutics **2023**, *15*, 301 4 of 17

antifouling bactericidal activity (concentration =  $1.9 \ \mu g \cdot mm^{-2}$ , or  $0.25 \ mg$  per disc) (see Figure S5).

#### 2.2.2. MOF Characterization

X-ray powder diffraction (XRPD) patterns of AgBDC were collected in an Empyrean PANalytical® powder diffractometer (PANalytical, Lelyweg, The Netherlands) in reflexion mode with a Cu K $\alpha$  = 1.5406 Å. The XR diagrams were carried out with a 20 scan between  $3-90^{\circ}$ , with a step size of  $0.013^{\circ}$  and a scanning speed of  $0.1^{\circ} \cdot \text{s}^{-1}$ . The Fourier transform infrared (FTIR) spectra (4000–650 cm<sup>-1</sup>) were obtained with a resolution of 2 cm<sup>-1</sup> at RT on a Bruker Tensor-27 spectrometer (Bruker, Billerica, MA, USA), fitted with a DTGS detector (Bruker, Billerica, MA, USA). The FTIR spectra were recorded through the attenuated total reflectance (ATR) technique. Thermogravimetric analyses (TGA) were carried out in an SDT Q-600 thermobalance (TA Instruments, New Castle, DE, USA) with a general heating profile from 30 to 600 °C with a heating rate of 5 °C·min<sup>-1</sup> under air using a flux of 100 mL·min<sup>-1</sup>. Note here that an air atmosphere was used to ensure the ligand decomposition and departure, as frequently used for MOF materials [45,46]. Quantitative determination of Ag content of the samples was conducted with inductively couple plasma optical emission spectroscopy (ICP-OES) on an Optima 3300 DV (PerkinElmer, Waltham, MA, USA); samples were thermally treated at 80 °C before digestion with HF and HNO<sub>3</sub>. Scanning electron microscopy (SEM) images of the AgBDC solid were taken with a Supra 55 VP (Carl Zeiss, Jena, Germany) field emission gun (FEG)-SEM after metallization of the samples. Dynamic light scattering (DLS) and  $\xi$ -potential (ZP) was registered via electrophoretic light scattering (ELS) using a Zetasizer Nano series Nano-ZS (Malvern Instruments, Worcestershire, UK). The particles were dispersed in the liquid media (methanol, ethanol, acetonitrile and water) at a concentration of 0.1 mg·mL<sup>-1</sup> using an ultrasound tip (UP400S, Hilscher, Teltow, Germany) with 30% amplitude for 40 s.

#### 2.3. MOF Stability Performance

# 2.3.1. AgBDC MOF Suspension

Taking into account the AgBDC bacteriological application, both structural and colloidal stability of MOF suspensions in DI  $\rm H_2O$  and NB were assessed. For XRD analysis, AgBDC suspensions (4000 ppm) were incubated for 18 h at 37 °C. The solid was recovered by centrifugation (4032×g RCF, 10 min) and it was dried at 50 °C prior to the analysis. Particle size and ZP of AgBDC suspensions were evaluated by DLS measurements during different time points (0, 0.25, 0.5, 1, 2, 5, 8 and 18 h) under stirring conditions (2000 ppm).

#### 2.3.2. AgBDC MOF Thin Film

The adhesion stability of AgBDC thin film to the glass substrate was monitored over the time (up to 7 days) in 2.5 mL of NB at 37 °C (at 100 ppm of AgBDC), determining particle size and ZP by DLS in contact with this NB medium. Additionally, MOF chemical stability was analyzed by means of the BDC ligand release (wt.%) to the NB media, quantified via high-performance liquid chromatography (HPLC): a reversed phase HPLC Jasco LC-4000 series system, equipped with a PDA detector MD-4015 and a multisampler AS-4150 controlled by ChromNav software (Jasco Inc., Tokyo, Japan). A purple ODS reverse-phase column (5  $\mu$ m, 4.6  $\times$  150 mm<sup>2</sup>, Análisis Vínicos, Tomelloso, Spain) was employed, using an isocratic condition, with the flow rate at 1 mL·min<sup>-1</sup>, injection volume of 30 μL and the column temperature fixed at 25 °C. The mobile phase was based on a mixture of 50:50 MeOH:phosphate-buffered solution (PBS; 0.04 M, pH = 2.5) with a retention time (Rt) and maximum of absorption at 3.10 min and 240 nm, respectively (see Supplementary Materials, Figure S7). The PBS preparation (0.04 M, pH = 2.5) was based on 0.02 mol (2.4 g) of NaH<sub>2</sub>PO<sub>4</sub> and 0.02 mol (2.84 g) of Na<sub>2</sub>HPO<sub>4</sub> were dissolved in 1 L of DI water. The pH was then adjusted to 2.5 with  $H_3PO_4$  ( $\geq 85\%$ ). Given the low solubility of the BDC linker in aqueous solution and in order to avoid any potential underestimation during the stability test, 1.5 mL of the contact medium were taken after diverse time points (0.75, 2, 4

Pharmaceutics **2023**, *15*, 301 5 of 17

and 7 days), being evaporated at  $100\,^{\circ}$ C. Afterwards, they were solubilized in  $1.5\,\text{mL}$  of methanol (MeOH), making them ready for HPLC analysis.

#### 2.4. Bactericidal Activity and Biofilm Inhibition

# 2.4.1. Microorganism Tests

Escherichia coli (E. coli) strain (CET 516, strain designation ATCC 8739) was employed to develop microbiological tests as a representative of biofilm-forming bacteria. They were kept frozen ( $-20\,^{\circ}$ C) until use. The microorganism was activated by growing it in 25 mL Erlenmeyer of nutrient broth (NB, no Cl, beef extract 5 g·L $^{-1}$ , peptone 10 g·L $^{-1}$ , pH = 7–7.2) under stirring conditions (100 rpm) at 37 °C. Inoculums were diluted with fresh NB<sub>l</sub> at 10<sup>6</sup> bacteria·mL $^{-1}$  (tracked by measuring optical density at 600 nm, OD<sub>600</sub>, with a Shimadzu UV-1800 spectrophotometer (Shimadzu, Kyoto, Japan)) to preserve the exponentially growing phase of the microorganisms during the total incubation time. For comparison purposes, *Staphylococcus aureus* (*S. aureus*) (CETC 240, strain designation ATCC 6538P) was also cultivated in the same manner.

# 2.4.2. Inhibition Halo Experiments

An antimicrobial effect was firstly evaluated using the agar diffusion method. For the diffusion tests, 20 ppm of MOF AgBDC were placed on the surface of soft agar plates (Petri dishes,  $\emptyset$  = 9 cm), previously inoculated with 0.6 mL of  $10^6$  colony-forming units (CFU) mL $^{-1}$  of *E. coli* and *S. aureus* bacterial suspensions, respectively, for 20 min at RT. They were incubated for 7 days at 37 °C, and the plates were digitally photographed at predetermined time intervals (18, 24, 48 h and 7 days) for determining the inhibition zones by measuring the halos with the software Image J. Additionally, the MOF precursors (AgNO<sub>3</sub> and BDC) were used as controls in proportional concentrations of the bulk material (17 and 9 ppm for 20 ppm of MOF, respectively). All experiments were repeated at least three times [47].

# 2.4.3. Suspension Assay against Planktonic Bacteria

Diverse concentrations of AgBDC MOF powder (1, 2.5, 5, 10, 20, 50, 100 and 200 ppm) were suspended over 2.25 mL of the previously mentioned  $10^6$  bacteria mL<sup>-1</sup> *E. coli* inoculums on a disposable 24-well plate for 18 h at 37 °C. Once again, AgNO<sub>3</sub> and BDC ligands were used as controls in proportional concentrations (i.e., for 20 ppm of MOF, 9 and 17 ppm of ligand and AgNO<sub>3</sub>, respectively). These inoculums with MOF suspensions were used for determining planktonic bacteria viability by optical density (OD<sub>600</sub>), colony counting (colony forming units, CFU) and enzymatic activity (fluorescein diacetate, FDA) [40,48].

The optical density was determined with aliquots of the suspensions of the controls and the sample in contact with the bacteria, measuring the absorbance (OD<sub>600</sub>;  $\lambda$  = 600 nm) in a UV-1800 spectrophotometer. Results are represented as % of inhibition. The colony count was performed from the aliquots (of both planktonic and sessile bacteria) that were placed in sterile 96-well microtiter plates in 10-fold serial dilutions in PBS. The amount of 10  $\mu$ L were inoculated into Petri dishes (Ø = 9 cm), containing NB agar composed of glucose, yeast extract and tryptone. Finally, they were incubated at 37 °C for 24 h, and bacterial growth was quantified using a CL-1110 counting instrument (Acequilabs, Spain). All experiments were carried out in duplicate or triplicate and in accordance with ISO 22196. Results are presented as the ratio of the Log<sub>10</sub> CFU·mL<sup>-1</sup> of the sample vs. the control.

Pharmaceutics **2023**, 15, 301 6 of 17

Finally, the enzymatic activity was evaluated, determined using FDA, a nonfluorescent compound hydrolyzed by esterases in fully functional cells to a green, fluorescent compound, fluorescein. For doing so, 5  $\mu L$  of a prepared FDA solution at 2 mg·mL $^{-1}$  was mixed in dimethyl sulfoxide (DMSO) along with 195  $\mu L$  of the sample bacteria suspension in a 96-well plate. The plate was incubated at 25 °C for 30 min, with readings performed every 5 min (exc. 485 nm; em. 528 nm) using an Fluoroskan Acent FL model fluorometer, (Thermo Scientific brand, Waltham, MA, USA). The possible interference of the culture medium and the MOF with the fluorescence measurement was determined before checking the activity. Each sample was measured four times, and the results are presented as reduction %.

# 2.4.4. Thin-Film Assay against Sessile E. coli Biofilm

AgBDC thin films (at 100 ppm as final MOF concentration) along with their controls (glass discs without material) were put in contact with 2.5 mL of the previously mentioned  $E.\ coli$  inoculums in 24 well-plates at 37 °C for 18 h and 7 days, displacing the discs with the active layer facing up and while remaining at the bottom without floating. Supernatant liquid was used for OD $_{600}$  and FDA measurement, analyzing the bacteria colony forming cell (CFC) considered to be planktonic bacteria, and the cells removed from the biofilm formed over the cover glasses were considered to be the sessile type. For the removal of the sessile bacteria from the cover glasses, a previously reported procedure was followed [49].

Furthermore, because of the potential antiadherent and antibacterial properties of the AgBDC thin films, their activity was evaluated via the confocal laser scanning microscopy (CLSM) technique. After incubation of the cover glasses with the mentioned *E. coli* inoculum during 90 min and 48 h, the discs were washed three times with sterile PBS, staining them with 3  $\mu$ L·mL<sup>-1</sup> of Live/Dead<sup>®</sup> Bacterial viability kit (BacklightTM; which contains a mixture of Syto 9 and propidium iodide, PI). Additionally, 5  $\mu$ L·mL<sup>-1</sup> of calcofluor solution was added to label "in blue" the mucopolysaccharides of the biofilm (extracellular matrix), which specifically determine the biofilm formation. Both reactants were incubated for 15 min at RT. Confocal images were obtained using an Olympus FV1200 (Tokyo, Japan) confocal microscope, collecting 8 photographs (60× magnification) of each sample. This technique identifies the bacterial viability through the integrity of the cell membrane: viable bacteria emit *green* fluorescence due to Syto 9 fluorochrome ( $\lambda$ ex 480 nm/ $\lambda$ em 500 nm), while nonviable bacteria emit *red* fluorescence due to PI ( $\lambda$ ex 490 nm/ $\lambda$ em 635 nm). In addition, the formation of biofilm is revealed in blue ( $\lambda$ ex 350 nm/ $\lambda$ em 432 nm) [50]. All images are representative of three independent experiments.


Antifouling capacity of the materials was likewise assessed using an SEM system (DSM-950 Zeiss, Oberkochen, Germany). For SEM micrographs, samples were washed twice with PBS to remove nonattached bacteria from the surface (AgBDC thin film and control glass disc). Next, the remaining bacteria were fixed in glutaraldehyde (2.5%) for 2 h and then dehydrated with gradient ethanol (30–100%) and acetone. Each sample was dried with hexamethyldisilazane for 15 min prior to sputter coating with gold for SEM observation. All images are representative of three independent experiments.

#### 3. Results and Discussion

# 3.1. Synthesis and Characterization

The AgBDC MOF was first reported by Sun et al. [41]. Nevertheless, in this work, the synthetic procedure was optimized (see Section 2) in order to avoid solvent heating, reducing the reaction time (1 vs. 7 days) and upscaling the AgBDC production per reaction batch (250 vs. 10 mg) [51]. Thus, this simpler and faster method procured a grey-brownish crystalline powder that perfectly matched the structure of the previously reported silver terephthalate coordination polymer AgBDC (see X-ray diffraction patterns–XRPD in Figure 1) [41].

Pharmaceutics **2023**, 15, 301 7 of 17



**Figure 1.** Characterization of synthesized AgBDC MOF. (a) XRPD patterns of as-synthesized AgBDC (up) compared to the simulated reference (down). (b) TGA and (c,d) SEM micrographs of AgBDC samples. Scale bar: 1 μm (c) and 200 nm (d).

Further analyses of AgBDC indicated that the material exhibited a slight weight loss up to ~300 °C (see TGA, Figure 1). Afterwards, the decomposition profile showed an important weight loss of ~42% corresponding to the departure of the organic linker. The remaining solid residue, identified as Ag° (Figure S2), showed a slightly lower Ag content (53 wt.%) in comparison with the theoretical formula of AgBDC (56 wt.% for AgC<sub>4</sub>H<sub>2</sub>O<sub>2</sub>) [45,46,51,52]. This divergence might arise due to the presence of an extra ligand, presumably attached to Ag at the boundaries of crystallites, covering the Ag centers from water molecules, which is in line with TGA results of a hydrophobic material [53]. Despite this variation, the TGA value was in agreement with the amount of silver determined through inductively coupled plasma optical emission spectroscopy (ICP-OES), 52.3  $\pm$  2.1 wt.%. Field emission gun scanning electron microscopy (FEG-SEM) images showed submicrometric and slightly defined grain-shaped crystals (between 250  $\pm$  210 nm) that tend to agglomerate in bigger particles (10  $\pm$  0.1  $\mu$ m; n ~200 particles were measured, see Figure 1). Even direct comparison with original synthesis is not possible, as no micrographs were presented; a recent work with a synthesis based on ammonia procured similar AgBDC crystals in shape and size [54].

# 3.2. AgBDC Stability Suspended in Biological Media

Bearing in mind the biocide application of AgBDC, it is crucial to investigate the maintenance of the MOF physicochemical features under relevant environments: mainly, its structural and colloidal stability in contact with physiological media such as deionized water or culture media (NB). These studies will shed light on its biological activity and suitability for the desired antimicrobial purposes. As can be seen in the XRPD patterns (see Supplementary Materials, Figure S3), AgBDC preserved its crystalline structure after 18 h at 37 °C in water or NB, the required conditions for the biological experiments. Regarding the evolution of the hydrodynamic particle diameter, dynamic light scattering (DLS) measurements were performed (disclosed in Table 1). In aqueous solution, a monodisperse submicrometric size (300  $\pm$  130 nm) was observed and was in good agreement with the obtained dimensions from FEG-SEM micrographs (250  $\pm$  210 nm). In more complex media (NB bacterial broth), the presence of other components such proteins, vitamins, etc., seems to partially stabilize the size, reaching smaller particle average in comparison

Pharmaceutics **2023**, 15, 301 8 of 17

with water ( $100\pm70$  vs.  $300\pm130$  nm), which is associated with higher polydispersity indexes (PdI; 0.45 vs. 0.30). In terms of the surface charge, strong negative values were obtained ( $-50\pm5$  and  $-30\pm1$  mV) for both media, probably because of the presence of carboxylate moieties on the surface. The  $\zeta$ -potential decreased in the case of NB growth due to the influence of the other medium compounds, which is also in agreement with the observed size variation [47]. As reported by Moore et al. [48], when nanoparticles are dispersed in culture media, proteins are strongly adsorbed on the surface (forming the so-called protein corona), which affects the surface charge distribution and, subsequently, the colloidal stability. This effect has been also observed in other MOF formulations, where the control of their biodistribution with diverse biopolymers was performed [49]. Moreover, these analyses were monitored after 18 h of contact time (see Supplementary Materials, Figure S4), exhibiting high-quality stability values, indicating that AgBDC will be available in the suspension for bacteria inhibition.

**Table 1.** Colloidal characterization of AgBDC suspensions in water or NB at 37 °C.

Media	Hydrodynamic Particle Size (nm)	Polydispersity Index (PdI)	ζ-Potential (mV)	
H <sub>2</sub> O	$300 \pm 130$	$0.30 \pm 0.03$	$-50 \pm 5$	
NB	$100 \pm 70$	$0.45 \pm 0.01$	$-30 \pm 1$	

#### 3.3. AgBDC Thin-Film Stability in Biological Media


More interesting and challenging than the antimicrobial treatment of planktonic bacteria (in suspension) is the development of antiadherent and biocide surfaces that could both prevent and treat bacterial biofouling. This is the reason why AgBDC MOF was deposited by spin coating on glass disc substrates to form an active thin-film coating (see Section 2 and thin-film images in Supplementary Materials, Figure S5). Here, DLS measurements were also used to assess the potential detachment of the AgBDC particles from the thin film after the contact with the NB for 7 days by determining the particle size in the supernatant NB medium (see Supplementary Materials, Figure S6). As the diameter of the particles detected was around  $10 \pm 8$  nm, which is an order of magnitude below the AgBDC MOF crystal size, it was concluded that the DLS just quantified the protein size from the NB (i.e., a blank experiment of NB without any MOF had an average size of  $5 \pm 3$  nm). This size change over the time could be associated to its agglomeration and potential variation of its conformation [39]. Objects of 100–400 nm were not detected in NB, ruling out the release of the AgBDC particles and, consequently, concluding that AgBDC was strongly attached to the substrate, which remained available in the thin film during long periods of time (7 days).

Despite the fact that no AgBDC particles were released into the medium, the MOF constituents (i.e., Ag<sup>+</sup> and BDC) could still be released to the biological media by its decomposition. Bearing this in mind, researchers more frequently determine the silver ions delivery from Ag-based MOFs [50,51,55]. In this work, the supernatant in contact with the AgBDC thin-film coating was analyzed by quantifying not only the released Ag+ (by ICP-OES), but also the organic 1,4-benzene dicarboxylate (BDC) ligand (via HPLC).

It was observed that after the first 24 h, a fast BDC release (5 wt.% delivered from the total in the coating; Figure 2) was obtained with NB at 37 °C. After that time, it steadily reached a plateau of  $\sim$ 6 wt.% at 7 days. Considering the scarce amount of released BDC to the media after 7 days and the burst initial trend, it is believed that it corresponds to the excess of ligand attached to the boundaries of the AgBDC structure, already identified by TGA and ICP. On top of that, no release of Ag+ was detected during this period, being below the limit of detection (LOD; <0.05 ppm). Thus, due to the observed experimental findings, it could be concluded that the AgBDC coating was highly stable under the biocide experimental conditions, remaining strongly attached and available during the whole 7-day

Pharmaceutics **2023**, 15, 301 9 of 17

test. The high stability of the conformed AgBDC coating is in line with previously reported results for the amino-substituted AgBDC-NH<sub>2</sub> synthesized on top of a thin-film membrane, where just 0.4 ppm of Ag was released in 5 days under flux [15].



**Figure 2.** Degradation kinetics of AgBDC thin-film coating incubated in NB at 37 °C.

#### 3.4. Determination of AgBDC Bactericidal Activity

As a first attempt, the AgBDC biocide character against S. aureus and E. coli was investigated by an agar diffusion test (in solid shape), determining the inhibition halo produced by the presence of AgBDC together with the equivalent amount for the tested concentration of AgNO<sub>3</sub> and BDC, as main precursors. Representative images of the halo evolution over time are in SI (see Figure S8), while their quantification is presented in Figure 3. Remarkably, AgBDC had the potential to treat both S. aureus and E. coli infections, showing a higher effect on E. coli. A similar trend was reported for the aminated analogue AgBDC-NH2 deposited on membranes, observing a slighter inhibition effect when incubated with S. aureus compared to E. coli [17]. For both Gram (+) and Gram (-) bacteria, the inhibition halo formed by the powdered AgBDC was not only maintained, but also boosted during the 7 days of experiment. As mentioned in the state of the article, when studying other Ag-based MOFs inhibition, most agar tests consider the measurement of the area just in a single time (overnight or 24 h of incubation); thus, a direct comparison is not straight forward [17,20,21]. An example of a long time examination was reported for the silver-triazole coordination polymer Ag-TAZ [56]. When exposed also in powder form against Anabaena and Synechoccus cyanobacteria, the inhibition zone remained constant with time. This emphasizes the appealing biocidal activity of AgBDC that is not only kept over time, but also is able to prolong and boost its performance.




Figure 3. Inhibition halo (mm; determined by Image J) of AgBDC against: (a) S. aureus and (b) E. coli.


In the particular case of the AgNO<sub>3</sub> control, a higher inhibition compared to the whole MOF was exhibited. This behavior could be explained by the greater availability

Pharmaceutics **2023**, *15*, 301 10 of 17

of cation Ag<sup>+</sup> in the Petri dish due to the higher solubility of the silver salt compared to the MOF in water and agar [57]. This is in conformity with the exceptional stability of AgBDC, determined in the previous section. On the other side, the BDC ligand performed a lower inhibition compared to the MOF (i.e., after 1 day, the BDC diameter was 2.5 mm vs. 9.0 mm for *S. aureus* and 12.5 mm for *E. coli* in the case of AgBDC). Hence, the BDC ligand displayed some biocide characteristics against both bacterial strains; therefore, the AgBDC MOF bioactivity must arise from the silver present in its structure and the potential interaction of the MOF crystals with the bacteria membrane, as no release of this cation was detected under these working conditions.

However, the organic ligand showed some antibacterial activity (85 vs. 65% bacteria inhibition at 20 ppm from AgNO3 and BDC, respectively; Table S1), thus being also beneficial for the resulting bactericidal activity of the AgBDC MOF.

As agar diffusion assays indicated that AgBDC had a higher effect against E. coli (see Figure 3), this strain was selected for the following bactericidal experiments. Determination of the minimum inhibitory concentration (MIC) of AgBDC suspension against planktonic E. coli was determined by counting the CFU against growing concentrations of AgBDC suspensions (Figure 4). From these data, an MIC within the 100–200 ppm range (corresponding to 50–100 ppm of Ag<sup>+</sup> alone) could be estimated. Despite this being a relatively high Ag<sup>+</sup> concentration compared to other Ag-based MOFs (see SI, Table S2), it should be highlighted that the elevated stability of AgBDC under biological media might favor: (i) a minimum Ag<sup>+</sup> leaching to the NB over extended periods of time, and (ii) the lower bactericidal or extra inhibition effect coming from the ligand release (see SI, Table S1). In contrast with those other reported structures, whose activity arises from Ag<sup>+</sup> diffusion through the bacteria membrane and, subsequently, reactive oxygen species (ROS) generation [8,58,59], AgBDC particles might be the principal trigger for the observed *E. coli* bacteria impact. In this sense, complementary bacterial viability assays were performed, such as determination of  $OD_{600}$  and the reduction of enzymatic activity by fluorescent fluorescein diacetate (FDA). These outcomes showed similar CFU rates as previously obtained, with a clear dependentconcentration increase in the bacteria inhibition produced by AgBDC, which was similar to the AgNO<sub>3</sub> control effect (see SI, Figure S9).



B) Sample	Concentration (ppm)	CFU·mL⁻¹	Inhibition (%)	Log <sub>10</sub> (CFU mL <sup>-1</sup> )
Control	0	5.78E9	0.00	9.76
AgBDC	1	5.84E9	0.00	9.77
	2.5	2.70E9	53.25	9.43
	5	2.33E9	59.77	9.36
	10	6.88E8	88.10	8.83
	20	8.55E7	98.52	7.93
	50	7.79E7	98.65	7.89
	100	1.60E5	99.99	5.20
	200	3.55E2	99.99999	2.55

**Figure 4.** (**A**) *E. coli* CFU·mL $^{-1}$  (represented as the logarithmic ratio, with C0 being the CFU·mL $^{-1}$  of the positive control for better comparison) in contact with AgBDC suspension after 18 h of incubation. (**B**) Determination of planktonic *E. coli* bacterial viability by plate count after 18 h in contact with the AgBDC suspension: the correlation between CFU·mL $^{-1}$ , Log<sub>10</sub> and inhibition %.

Pharmaceutics **2023**, *15*, 301 11 of 17

Because the main interest of this work is to investigate the potential inhibition of challenging biofilms, as a step further, AgBDC thin-film coatings were incubated with  $E.\ coli$  inoculum in order to evaluate its capability to face the biofouling (see, in SI, Figure S10). For the study, both types of bacteria, the ones in suspension (planktonic bacteria) together with the biofilm-forming type detached from the surface (sessile bacteria), were quantified (see Table 2). AgBDC thin-film coatings (100 ppm under the experiment conditions) exhibited a strong biocide effect, even after 18 h of incubation, providing a fruitful activity against planktonic  $E.\ coli$  with a 99.9999% inhibition of the culture growth. A similar powerful effect was observed versus sessile  $E.\ coli$ , as viable CFU in contact with AgBDC is three orders of magnitude lower than the ones detached from a control glass disc (9.17  $\times$  10<sup>1</sup> vs.  $5.72 \times 10^4\ CFU \cdot mL^{-1}$ , respectively). In other words, a 99.84% viable biofilm inhibition was achieved.

**Table 2.** Determination of planktonic and sessile *E. coli* bacterial viability by plate counting after 18 h (0.75 days in dark) or 7 days contact with the different proposed materials, expressed as  $CFU \cdot mL^{-1}$ , inhibition % (with respect to the control  $CFU \cdot mL^{-1}$ ) and  $Log_{10}$  ( $CFU \cdot mL^{-1}$ ).


		Planktonic Bacteria			Sessile Bacteria		
Sample	Contact Time	CFU⋅mL <sup>-1</sup>	Inhibition (%)	$Log_{10} \ (CFU \cdot mL^{-1})$	CFU·mL <sup>−1</sup>	Inhibition (%)	$Log_{10}$ (CFU·mL $^{-1}$ )
Control	<1 day	$2.70 \times 10^{9}$	0.0000	9.43	$5.72 \times 10^4$	0.0000	4.76
AgBDC		$1.57 \times 10^{3}$	99.9999	3.20	$9.17 \times 10^{1}$	99.84	1.96
Control	7 days	$2.42 \times 10^{11}$	0.0000	11.38	$1.53\times10^{10}$	0.0000	10.18
AgBDC		$3.20 \times 10^{4}$	99.99999	4.51	$3.38 \times 10^{3}$	99.9999	3.53

Considering that the CFU logarithmic ratio (average value of  $\sim$ 0.4 for both suspension and biofilm viable bacteria) in contact with AgBDC thin-film coating (see SI, Figure S11) exhibited the same range as for AgBDC suspensions at 100 ppm (see Figure 4), this could imply that AgBDC biocide activity is not diminished after the thin-film conformation. Moreover, an important bacterial inhibition (>80%) of the planktonic *E. coli* obtained was also confirmed in the supernatant after the MOF contact via OD<sub>600</sub>, observing a decrease in their enzymatic activity ( $\sim$ 70% reduction of the FDA fluorescent emission; see SI, Figure S12).

As was previously observed with the agar diffusion test, the antimicrobial effect of AgBDC coating was kept after 7 days of incubation with an additional inhibition boost for both sessile and planktonic *E. coli*. Even other Ag-MOF coatings have previously been considered as potential treatments for bacterial biofouling; prior literature often assesses the biocide effect of the coatings qualitatively by means of visualizing the surface by confocal microscopy just after a brief incubation period (from 1 to 24 h) [17,19,22]. However, it is highly recommendable to extend the study timeline for its approval, as has been conducted in this publication. In addition, for an effective quantification of the system, it is necessary to ensure the biocide activity of the coating during the complete lifetime of the MOF device (e.g., water filtration membranes, wound healing patches, coatings) [23,60].

As important as the antimicrobial character of the AgBDC coating for the inhibition of challenging *E. coli* biofilm are its antiadherent properties. Observation of the biofilm growth with the assistance of SEM (see Figure 5) reveals attached *E. coli* bacteria to the control glass substrate, which starts to agglomerate in a colony form after 18 h. In contrast, in the case of the AgBDC coatings, very few and isolated *E. coli* bacteria are spotted (marked in Figure 5 for better visualization). Under higher magnification, the attached *E. coli* exhibits a rough membrane surface compared to the control. This alteration could be due to the potential stress of the bacteria in contact with the AgBDC coating, leading to bacterial death, as previously stated by other authors [19,21,24].

Pharmaceutics **2023**, *15*, 301




**Figure 5.** SEM images of *E. coli* biofilm on cover glass surface: AgBDC coating (**right**) after biofilm growth for 18 h (**up**) and 7 days (**down**) compared with the control (**left**); zoom images (2 μm scale) are highlighted (squared, **right**).

Monitoring the *E. coli* biofilm growth in the control after 7 days revealed a higher amount of bacteria colonization on the surface. Even more, with higher magnification, the formation of extracellular polymeric substances (EPS) binding along with the microbial aggregation was confirmed. Conversely, no sight of *E. coli* was found over the AgBDC coating, verifying the long-time biocide and antifouling performance of this AgBDC coating.

In addition, the effectiveness of AgBDC coating preventing bacterial adhesion (antifouling) and its antimicrobial capacity were also evaluated by confocal laser scanning microscopy (CLSM). As a distinctive feature of the CLSM analysis presented by other researchers when analyzing MOFs as bactericidal agent, here, the use of calcofluor for specifically staining the EPS matrix of a biofilm along with the well-known fluorochromes Syto 9 and PI (Live/Dead kits) is originally reported [61,62]. Even if the determination of bacteria viability (red-green) is vital for analyzing the MOF bactericide effect, it is also required to assess the MOF biofilm inhibition ability (i.e., preventing EPS formation or the dispersion of the mucopolysaccharides after biofilm destruction), which appears in blue in the CLSM micrographs. Representative images of the AgBDC effect on E. coli biofilm are depicted in Figure 6. After 90 min, live bacteria colonies appeared in the control disc (in green), starting their adhesion to the substrate. After this time, almost no attached bacteria cells were appreciated to the AgBDC coating, neither in the confocal (bottom right) nor in the transmission mode (bottom left). Therefore, these findings determined the capability of AgBDC MOF to restrain E. coli initial bacterial adhesion. Furthermore, it caused bacterial death to those in contact, as seen in red-stained bacteria from the CLSM image, which is in agreement with the CFU analysis.

Remarkably, the antifouling properties of the AgBDC coating were sustained even after 48 h of incubation. At this time, the untreated control sample displayed the typical structure of a healthy *E. coli* biofilm composed of colony live bacteria (green) integrated in a protective mucopolysaccharide matrix (blue). In contrast, the MOF-coated substrate led to the absence of *E. coli* bacteria attached to the surface, not even observing any killed bacteria with the red fluorescent staining. In consequence, as no bacteria were adhered, no biofilm (blue-stained mucopolysaccharides) proliferation was promoted. In other words, these outcomes indicated that AgBDC not only prevented bacterial adhesion, but also their biofilm formation.

Pharmaceutics **2023**, 15, 301 13 of 17



**Figure 6.** Fluorescence LIVE/DEAD confocal images of sessile *E. coli* biofilm (bottom right) and transmission mode (bottom left) on cover glass surface were taken after 1.5 h («bacterial adhesion») and 48 h («biofilm growth») of contact with AgBDC thin films (100 ppm; bottom). The MOF absence was used as control (top), highlighting with specific staining the bacterial viability (viable: green; dead: red) and the biofilm formation (blue). The scale bar corresponds to 20  $\mu$ m. All the images were taken at 63×.

These qualitative results have uniformity with the observations of the AgBDC coating obtained by SEM, which, along with the quantitative determination of bacterial viability, highlight the strong potential of the AgBDC MOF for the antimicrobial treatment of *E. coli*, showing a combined antifouling and biocide effect during long time periods (7 days). The capacity of AgBDC to prevent initial bacterial adhesion is a remarkable feature not reported so far for other Ag-based MOFs against biofilm formation (see Table S2) and scarcely mentioned for other antimicrobial MOFs (pure or as composites) [39,63].

# 4. Conclusions

The up-scaled protocol here described for the synthesis of AgBDC is a simple and quick methodology for the production of submicronic crystals ( $\sim$ 250 nm), which could be easily conformed in thin-film coatings. AgBDC exhibited great (colloidal, structural and chemical) stability in water and biological culture broth media up to 7 days, with a relevant biocide activity against *S. aureus* and *E. coli* strains (MIC<sub>E. coli</sub>  $\sim$  100 ppm).

Further, AgBDC thin-film coatings originally presented an important antifouling effect, preventing not only the *E. coli* bacteria initial adhesion to substrates but also inhibiting the proliferation of challenging biofilms. The AgBDC coatings were able to inhibit > 99% of bacterial viability, both in planktonic and sessile state. Altogether, its antiadherent and biocide properties make AgBDC a promising multifunctional material for the development of coatings for the attainment of bacteria-free surfaces, which is very useful in relevant applications (e.g., disease spread control, implants, food packaging, water treatment, heat exchange and biocorrosion).

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics15010301/s1. In the supporting information are additional results of material characterization (FTIR, Figure S1), stability (XRD, DLS, HPLC; Figures S2–S7, Table S1) and bactericidal activity of the AgBDC suspensions and thin-film coatings (inhibition halo, CFU, OD600, FDA; Figures S8–S12, Tables S1 and S2). A table comparing the present work with previous state of the art of biocide Ag-based MOFs is also included.

Pharmaceutics **2023**, 15, 301 14 of 17

**Author Contributions:** A.A.-V. and V.C.A. contributed equally to this work. P.H. contributed to the concept of this work, discussion of the experimental results, and reagents/materials/analysis tools. V.C.A. contributed to the synthesis and characterization of the materials, as well as the antibacterial testing. A.A.-V. conceived and designed the experiments, performed antibacterial testing, and analyzed the data. H.I.B., T.H. and S.L.-S. performed the synthesis and characterization of the materials and analyzed the data. G.A. and R.R. contributed to the antibacterial studies. I.I.-B. and M.V.-R. contributed to the evaluation of the antifouling properties. A.A.-V. prepared the first manuscript draft. All authors have read and agreed to the published version of the manuscript.

**Funding:** Funding was received from the following: MOFseidon project (PID2019-104228RB-I00, MCIN/AEI/10.13039/501100011033). VIRMOF-CM project associated with R&D projects in response to COVID-19 from "Comunidad de Madrid" and European Regional Development Fund—FEDER 2014-2020-OE REACT-UE 1. The Multifunctional Metallodrugs in Diagnosis and Therapy Network (MICIU, RED2018-102471-T). European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 897678. A1-S-31186 and 243224 projects under Basic Sciences SEP-CONACyT funding. CONACyT scholarship (No agreement 660046) and European Research Council (Advanced Grant VERDI; ERC-2015-AdG Proposal No 694160).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: This work was supported by the project MOFseidon PID2019-104228RB-I00, founded by MCIN/AEI/10.13039/501100011033. The authors acknowledge the "Comunidad de Madrid" and European Regional Development Fund—FEDER 2014-2020-OE REACT-UE 1—for their financial support to the VIRMOF-CM project associated with R&D projects in response to COVID-19. T.H. and P.H. acknowledge the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement (No. 897678). This work was also supported through Basic Sciences SEP-CONACyT funding with projects A1-S-31186 and 243224, and CONACyT scholarship (660046). We also acknowledge UAM for financial support. M.V.-R. acknowledges funding from the European Research Council (Advanced Grant VERDI; ERC-2015-AdG Proposal No. 694160).

Conflicts of Interest: The authors declare no conflict of interest.

#### References

- 1. Macià, M.D.; Luis, J.; Díez-aguilar, M. Microbiological Diagnosis of Biofilm-Related Infections. *Enferm. Infecc. Microbiol. Clin.* **2018**, *36*, 375–381. [CrossRef] [PubMed]
- 2. Bordi, C.; de Bentzmann, S. Hacking into Bacterial Biofilms: A New Therapeutic Challenge. *Ann. Intensive Care* **2011**, *1*, 19. [CrossRef] [PubMed]
- 3. Habash, M.; Reid, G. Microbial Biofilms: Their Development and Significance for Medical Device-Related Infections. *J. Clin. Pharmacol.* **1999**, *39*, 887–898. [CrossRef] [PubMed]
- 4. Davies, D. Understanding Biofilm Resistance to Antibacterial Agents. Nat. Rev. Drug Discov. 2003, 2, 114–122. [CrossRef]
- 5. Flemming, H.C.; Neu, T.R.; Wozniak, D.J. The EPS Matrix: The "House of Biofilm Cells. *J. Bacteriol.* **2007**, *189*, 7945–7947. [CrossRef]
- 6. Cloutier, M.; Mantovani, D.; Rosei, F. Antibacterial Coatings: Challenges, Perspectives, and Opportunities. *Trends Biotechnol.* **2015**, 33, 637–652. [CrossRef] [PubMed]
- 7. Furukawa, H.; Cordova, K.E.; O'Keeffe, M.; Yaghi, O.M. The Chemistry and Applications of Metal-Organic Frameworks. *Science* **2013**, *341*, 1230444. [CrossRef]
- 8. Wyszogrodzka, G.; Marszałek, B.; Gil, B.; Dorożyński, P. Metal-Organic Frameworks: Mechanisms of Antibacterial Action and Potential Applications. *Drug Discov. Today* **2016**, *21*, 1009–1018. [CrossRef] [PubMed]
- 9. Pettinari, C.; Pettinari, R.; Di Nicola, C.; Tombesi, A.; Scuri, S.; Marchetti, F. Antimicrobial MOFs. *Coord. Chem. Rev.* **2021**, 446, 214121. [CrossRef]
- 10. Arenas-Vivo, A.; Horcajada, P. Antimicrobial Metal Organic Frameworks. In Metal Organic Frameworks. Mittal, D.V., Ed.; Central West Publishing: Orange, Australia, 2019; pp. 1–34. ISBN 978-1-925823-57-8.
- 11. Rojas, S.; Arenas-vivo, A.; Horcajada, P. Metal-Organic Frameworks: A Novel Platform for Combined Advanced Therapies. *Coord. Chem. Rev.* **2019**, *388*, 202–226. [CrossRef]
- 12. Marambio-Jones, C.; Hoek, E.M.V. A Review of the Antibacterial Effects of Silver Nanomaterials and Potential Implications for Human Health and the Environment. *J. Nanopart. Res.* **2010**, *12*, 1531–1551. [CrossRef]

Pharmaceutics **2023**, 15, 301 15 of 17

13. Chernousova, S.; Epple, M. Silver as Antibacterial Agent: Ion, Nanoparticle, and Metal. *Angew. Chem. Int. Ed.* **2013**, *52*, 1636–1653. [CrossRef]

- 14. Zirehpour, A.; Rahimpour, A.; Arabi, A.; Gh, M.S.; Soroush, M. Mitigation of Thin Film Composite Membrane Biofouling via Immobilizing Nano-Sized Biocidal Reservoirs in the Membrane Active Layer Mitigation of Thin Film Composite Membrane Biofouling via Immobilizing Nano-Sized Biocidal Reservoirs in the Membrane Active. *Environ. Sci. Technol.* 2017, 51, 5511–5522. [CrossRef]
- 15. Firouzjaei, M.D.; Shamsabadi, A.A.; Aktij, S.A.; Seyedpour, S.F.; Sharifian, M.; Rahimpour, A.; Esfahani, M.R.; Ulbricht, M.; Soroush, M. Exploiting Synergetic Effects of Graphene Oxide and a Silver-Based Metal-Organic Framework to Enhance Antifouling and Anti-Biofouling Properties of Thin-Film Nanocomposite Membranes. *ACS Appl. Mater. Interfaces* **2018**, *10*, 42967–42978. [CrossRef]
- 16. Seyedpour, S.F.; Rahimpour, A.; Najafpour, G. Facile in-Situ Assembly of Silver-Based MOFs to Surface Functionalization of TFC Membrane: A Novel Approach toward Long-Lasting Biofouling Mitigation. *J. Memb. Sci.* **2019**, *573*, 257–269. [CrossRef]
- 17. Seyedpour, S.F.; Dadashi Firouzjaei, M.; Rahimpour, A.; Zolghadr, E.; Arabi Shamsabadi, A.; Das, P.; Akbari Afkhami, F.; Sadrzadeh, M.; Tiraferri, A.; Elliott, M. Toward Sustainable Tackling of Biofouling Implications and Improved Performance of TFC FO Membranes Modified by Ag-MOF Nanorods. *ACS Appl. Mater. Interfaces* **2020**, *12*, 38285–38298. [CrossRef]
- 18. Pejman, M.; Firouzjaei, M.D.; Aktij, S.A.; Das, P.; Zolghadr, E.; Jafarian, H.; Shamsabadi, A.A.; Elliott, M.; Esfahani, M.R.; Sangermano, M.; et al. Improved Antifouling and Antibacterial Properties of Forward Osmosis Membranes through Surface Modification with Zwitterions and Silver-Based Metal Organic Frameworks. *J. Memb. Sci.* 2020, 611, 118352. [CrossRef]
- 19. Zhang, S.; Ye, J.; Sun, Y.; Kang, J.; Liu, J.; Wang, Y.; Li, Y.; Zhang, L.; Ning, G. Electrospun Fibrous Mat Based on Silver (I) Metal-Organic Frameworks-Polylactic Acid for Bacterial Killing and Antibiotic-Free Wound Dressing. *Chem. Eng. J.* **2020**, 390, 124523. [CrossRef]
- Travlou, N.A.; Algarra, M.; Alcoholado, C.; Cifuentes-Rueda, M.; Labella, A.M.; Lazaro-Martínez, J.M.; Rodríguez-Castellon, E.; Bandosz, T.J. Carbon Quantum Dot Surface-Chemistry-Dependent Ag Release Governs the High Antibacterial Activity of Ag-Metal-Organic Framework Composites. ACS Appl. Bio Mater. 2018, 1, 693–707. [CrossRef]
- 21. Chu, H.Y.; Fu, H.; Liu, A.; Wang, P.; Cao, Y.L.; Du, A.F.; Wang, C.C. Two Silver-Based Coordination Polymers Constructed from Organic Carboxylate Acids and 4, 4'-Bipyridine-like Bidentate Ligands: Synthesis, Structure, and Antimicrobial Performances. *Polyhedron* 2020, 188, 114684. [CrossRef]
- 22. Pejman, M.; Dadashi Firouzjaei, M.; Aghapour Aktij, S.; Zolghadr, E.; Das, P.; Elliott, M.; Sadrzadeh, M.; Sangermano, M.; Rahimpour, A.; Tiraferri, A. Effective Strategy for UV-Mediated Grafting of Biocidal Ag-MOFs on Polymeric Membranes Aimed at Enhanced Water Ultrafiltration. *Chem. Eng. J.* **2021**, 426, 130704. [CrossRef]
- 23. Zhang, M.; Wang, G.; Wang, D.; Zheng, Y.; Li, Y.; Meng, W.; Zhang, X.; Du, F.; Lee, S. Ag@MOF-Loaded Chitosan Nanoparticle and Polyvinyl Alcohol/sodium Alginate/chitosan Bilayer Dressing for Wound Healing Applications. *Int. J. Biol. Macromol.* **2021**, 175, 481–494. [CrossRef] [PubMed]
- 24. Lu, X.; Ye, J.; Sun, Y.; Bogale, R.F.; Zhao, L.; Tian, P.; Ning, G. Ligand Effects on the Structural Dimensionality and Antibacterial Activities of Silver-Based Coordination Polymers. *Dalton Trans.* **2014**, *43*, 10104–10113. [CrossRef] [PubMed]
- 25. Liu, Y.; Xu, X.; Xia, Q.; Yuan, G.; He, Q.; Cui, Y. Multiple Topological Isomerism of Three-Connected Networks in Silver-Based Metal-Organoboron Frameworks. *Chem. Commun. Camb.* **2010**, *46*, 2608–2610. [CrossRef] [PubMed]
- 26. Berchel, M.; Le Gall, T.; Denis, C.; Le Hir, S.; Quentel, F.; Elléouet, C.; Montier, T.; Rueff, J.-M.; Salaün, J.-Y.; Haelters, J.-P.; et al. A Silver-Based Metal–organic Framework Material as a "reservoir" of Bactericidal Metal Ions. *New J. Chem.* **2011**, *35*, 1000–1003. [CrossRef]
- Jaros, S.W.; Smoleński, P.; Guedes da Silva, M.F.C.; Florek, M.; Król, J.; Staroniewicz, Z.; Pombeiro, A.J.L.; Kirillov, A.M. New Silver BioMOFs Driven by 1,3,5-Triaza-7-Phosphaadamantane-7-Sulfide (PTA=S): Synthesis, Topological Analysis and Antimicrobial Activity. CrystEngComm 2013, 15, 8060–8064. [CrossRef]
- 28. Lu, X.; Ye, J.; Zhang, D.; Xie, R.; Feyisa, R.; Sun, Y.; Zhao, L.; Zhao, Q.; Ning, G. Silver Carboxylate Metal Organic Frameworks with Highly Antibacterial Activity and Biocompatibility. *J. Inorg. Biochem.* **2014**, *138*, 114–121. [CrossRef]
- 29. Aguado, S.; Quirós, J.; Canivet, J.; Farrusseng, D.; Boltes, K.; Rosal, R. Antimicrobial Activity of Cobalt Imidazolate Metal–Organic Frameworks. *Chemosphere* **2014**, *113*, 188–192. [CrossRef]
- 30. Firouzjaei, M.D.; Shamsabadi, A.A.; Sharifian Gh., M.; Rahimpour, A.; Soroush, M. A Novel Nanocomposite with Superior Antibacterial Activity: A Silver-Based Metal Organic Framework Embellished with Graphene Oxide. *Adv. Mater. Interfaces* **2018**, 5, 1701365. [CrossRef]
- 31. Seyedpour, S.F.; Arabi Shamsabadi, A.; Khoshhal Salestan, S.; Dadashi Firouzjaei, M.; Sharifian Gh, M.; Rahimpour, A.; Akbari Afkhami, F.; Shirzad Kebria, M.R.; Elliott, M.A.; Tiraferri, A.; et al. Tailoring the Biocidal Activity of Novel Silver-Based Metal Azolate Frameworks. *ACS Sustain. Chem. Eng.* **2020**, *8*, 7588–7599. [CrossRef]
- 32. Xie, B.P.; Chai, J.W.; Fan, C.; Ouyang, J.H.; Duan, W.J.; Sun, B.; Chen, J.; Yuan, L.X.; Xu, X.Q.; Chen, J.X. Water-Stable Silver-Based Metal-Organic Frameworks of Quaternized Carboxylates and Their Antimicrobial Activity. *ACS Appl. Bio Mater.* **2020**, *3*, 8525–8531. [CrossRef]
- 33. Pejman, M.; Dadashi Firouzjaei, M.; Aghapour Aktij, S.; Das, P.; Zolghadr, E.; Jafarian, H.; Shamsabadi, A.A.; Elliott, M.; Sadrzadeh, M.; Sangermano, M.; et al. In Situ Ag-MOF Growth on Pre-Grafted Zwitterions Imparts Outstanding Antifouling Properties to Forward Osmosis Membranes. ACS Appl. Mater. Interfaces 2020, 12, 36300. [CrossRef]

Pharmaceutics **2023**, 15, 301 16 of 17

34. Nakhaei, M.; Akhbari, K.; Phuruangrat, A. Synthesis and Characterization of Silver and Copper Metal–organic Hybrid Nanomaterials and Their Biological Application. *Colloid Polym. Sci.* **2021**, 229, 773–781. [CrossRef]

- 35. Yuan, G.; Tian, Y.; Wang, B.; You, X.; Liao, Y. Mitigation of Membrane Biofouling via Immobilizing Ag-MOFs on Composite Membrane Surface for Extractive Membrane Bioreactor. *Water Res.* **2022**, 209, 117940. [CrossRef]
- 36. Zang, Y.; Roberts, T.R.; Batchinsky, A.I.; Reynolds, M.M. Metal-Organic Framework Polymer Coating Inhibits Staphylococcus Aureus Attachment on Medical Circulation Tubing under Static and Dynamic Flow Conditions. *ACS Appl. Bio Mater.* **2020**, *3*, 3535–3543. [CrossRef]
- 37. Gu, Q.; Albert Ng, T.C.; Sun, Q.; Kotb Elshahawy, A.M.; Lyu, Z.; He, Z.; Zhang, L.; Ng, H.Y.; Zeng, K.; Wang, J. Heterogeneous ZIF-L Membranes with Improved Hydrophilicity and Anti-Bacterial Adhesion for Potential Application in Water Treatment. *RSC Adv.* 2019, *9*, 1591–1601. [CrossRef]
- 38. Liu, Z.; Wang, F.; Ren, J.; Qu, X. A Series of MOF/Ce-Based Nanozymes with Dual Enzyme-like Activity Disrupting Biofilms and Hindering Recolonization of Bacteria. *Biomaterials* **2019**, 208, 21–31. [CrossRef]
- 39. Qiu, H.; Pu, F.; Liu, Z.; Deng, Q.Q.; Sun, P.; Ren, J.; Qu, X. Depriving Bacterial Adhesion-Related Molecule to Inhibit Biofilm Formation Using CeO2-Decorated Metal-Organic Frameworks. *Small* **2019**, *15*, 1902522. [CrossRef]
- 40. Arenas-Vivo, A.; Amariei, G.; Aguado, S.; Rosal, R.; Horcajada, P. An Ag-Loaded Photoactive Nano-Metal Organic Framework as a Promising Biofilm Treatment. *Acta Biomater.* **2019**, *97*, 490–500. [CrossRef]
- 41. Sun, D.; Cao, R.; Bi, W.; Weng, J.; Hong, M.; Liang, Y. Syntheses and Characterizations of a Series of Silver-Carboxylate Polymers. *Inorg. Chim. Acta* **2004**, 357, 991–1001. [CrossRef]
- 42. Martínez-Pastor, J.C.; Muñoz-Mahamud, E.; Vilchez, F.; García-Ramiro, S.; Bori, G.; Sierra, J.; Martínez, J.A.; Font, L.; Mensa, J.; Soriano, A. Outcome of Acute Prosthetic Joint Infections due to Gram-Negative Bacilli Treated with Open Debridement and Retention of the Prosthesis. *Antimicrob. Agents Chemother.* 2009, 53, 4772–4777. [CrossRef] [PubMed]
- 43. Reffuveille, F.; Josse, J.; Vallé, Q.; Mongaret, C.; Gangloff, S.C. Staphylococcus Aureus Biofilms and Their Impact on the Medical Field. In *The Rise of Virulence and Antibiotic Resistance in Staphylococcus Aureus*; InTech: London, UK, 2017.
- 44. Sharma, G.; Sharma, S.; Sharma, P.; Chandola, D.; Dang, S.; Gupta, S.; Gabrani, R. Escherichia Coli Biofilm: Development and Therapeutic Strategies. *J. Appl. Microbiol.* **2016**, *121*, 309–319. [CrossRef] [PubMed]
- 45. Healy, C.; Patil, K.M.; Wilson, B.H.; Hermanspahn, L.; Harvey-Reid, N.C.; Howard, B.I.; Kleinjan, C.; Kolien, J.; Payet, F.; Telfer, S.G.; et al. The Thermal Stability of Metal-Organic Frameworks. *Coord. Chem. Rev.* 2020, 419, 213388. [CrossRef]
- 46. Lázaro, I.A. A Comprehensive Thermogravimetric Analysis Multifaceted Method for the Exact Determination of the Composition of Multifunctional Metal-Organic Framework Materials. *Eur. J. Inorg. Chem.* **2020**, 2020, 4284–4294. [CrossRef]
- 47. Quaresma, S.; André, V.; Antunes, A.M.M.; Vilela, S.M.F.; Amariei, G.; Arenas-Vivo, A.; Rosal, R.; Horcajada, P.; Duarte, M.T. Novel Antibacterial Azelaic Acid BioMOFs. *Cryst. Growth Des.* **2020**, *20*, 370–382. [CrossRef]
- 48. Amariei, G.; Kokol, V.; Vivod, V.; Boltes, K.; Letón, P.; Rosal, R. Biocompatible Antimicrobial Electrospun Nanofibers Functionalized with ε-Poly-L-Lysine. *Int. J. Pharm.* **2018**, 553, 141–148. [CrossRef]
- 49. Amariei, G.; Kokol, V.; Boltes, K.; Letón, P.; Rosal, R. Incorporation of Antimicrobial Peptides on Electrospun Nanofibres for Biomedical Applications. *RSC Adv.* **2018**, *8*, 28013–28023. [CrossRef]
- 50. González, B.; Colilla, M.; Díez, J.; Pedraza, D.; Guembe, M.; Izquierdo-Barba, I.; Vallet-Regí, M. Mesoporous Silica Nanoparticles Decorated with Polycationic Dendrimers for Infection Treatment. *Acta Biomater.* **2018**, *68*, 261–271. [CrossRef]
- 51. Celis-Arias, V.; Garduño-Wilchis, I.A.; Alarcón, G.; González Chávez, F.; Garrido Guerrero, E.; Beltrán, H.I.; Loera-Serna, S. Room-Temperature Synthesis of Nanometric and Luminescent Silver-MOFs. *Front. Chem.* **2023**, *10*, 1065622. [CrossRef]
- 52. Waterhouse, G.I.N.; Bowmaker, G.A.; Metson, J.B. The Thermal Decomposition of Silver (I, III) Oxide: A Combined XRD, FT-IR and Raman Spectroscopic Study. *Phys. Chem. Chem. Phys.* **2001**, *3*, 3838–3845. [CrossRef]
- 53. Vilela, S.; Salcedo-Abraira, P.; Colinet, I.; Salles, F.; de Koning, M.; Joosen, M.; Serre, C.; Horcajada, P. Nanometric MIL-125-NH2 Metal-Organic Framework as a Potential Nerve Agent Antidote Carrier. *Nanomaterials* **2017**, *7*, 321. [CrossRef]
- 54. Mandal, S.; Nanavati, S.P.; Willock, D.J.; Ananthakrishnan, R. Photoactive Ag(I)-Based Coordination Polymer as a Potential Semiconductor for Photocatalytic Water Splitting and Environmental Remediation: Experimental and Theoretical Approach. *J. Phys. Chem. C* 2019, 123, 23940–23950. [CrossRef]
- 55. Cao, H. Silver Nanoparticles for Antibacterial Devices: Biocomparibility and Toxicity; Cao, H., Ed.; CRC Press: Boca Raton, FL, USA, 2017; ISBN 1498725333.
- 56. Martín-Betancor, K.; Aguado, S.; Rodea-Palomares, I.; Tamayo-Belda, M.; Leganés, F.; Rosal, R.; Fernández-Piñas, F. Co, Zn and Ag-MOFs Evaluation as Biocidal Materials towards Photosynthetic Organisms. *Sci. Total Environ.* **2017**, *595*, 547–555. [CrossRef]
- 57. Gupta, A.; Maynes, M.; Silver, S. Effects of Halides on Plasmid-Mediated Silver Resistance in Escherichia Coli. *Appl. Environ. Microbiol.* **1998**, *64*, 5042–5045. [CrossRef]
- 58. Apel, K.; Hirt, H. Reactive Oxygen Species: Metabolism, Oxidative Stress, and Signal Transduction. *Annu. Rev. Plant Biol.* **2004**, 55, 373–399. [CrossRef]
- 59. Park, H.-J.; Kim, J.Y.; Kim, J.; Lee, J.-H.; Hahn, J.-S.; Gu, M.B.; Yoon, J. Silver-Ion-Mediated Reactive Oxygen Species Generation Affecting Bactericidal Activity. *Water Res.* **2009**, *43*, 1027–1032. [CrossRef]
- 60. Gong, J.-L.; Tan, Z.-K.; Fang, S.-Y.; Li, J.; Cao, W.-C.; Chen, Z.-P. Thin-Film Nanocomposite Membrane Incorporated by Ag-Mof: Improvement of Resistance to Biofouling for Dye Separation. *SSRN Electron. J.* **2022.** [CrossRef]

Pharmaceutics **2023**, *15*, 301 17 of 17

61. Stewart, P.S.; Murga, R.; Srinivasan, R.; de Beer, D. Biofilm Structural Heterogeneity Visualized by Three Microscopic Methods. *Water Res.* **1995**, *29*, 2006–2009. [CrossRef]

- 62. Neu, T.R.; Kuhlicke, U.; Lawrence, J.R. Assessment of Fluorochromes for Two-Photon Laser Scanning Microscopy of Biofilms. *Appl. Environ. Microbiol.* **2002**, *68*, 901–909. [CrossRef]
- 63. Li, R.; Chen, T.; Pan, X. Metal–Organic-Framework-Based Materials for Antimicrobial Applications. *ACS Nano* **2021**, *15*, 3808–3848. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.